Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...
The FDA expedited drug review activity in December 2025 includes six fast-tracked therapies and the first National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback